Company / SG&A Expense
Humana SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$15.4B
FY2025
5-year range
$10.1B / $15.4B
FY2021-FY2025
Trend
+12.8%
vs FY2024
Sector context
#4 of 158
Health Care
What the data says
Among 158 Health Care companies, Humana is in the bottom 3% for sg&a expense. SG&A Expense has increased for 3 consecutive years, from $10.1B in FY2022 to $15.4B in FY2025.
Based on SEC 10-K filings.
$15.4B in FY2025 with a 5-year CAGR of +9.0%. Top quartile in the Health Care sector.
Increased from $10.1B to $15.4B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +15.4%
- 5-Year CAGR
- +9.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 158This company $15.4B Sector average $175.9B
▼
-91.2% below sector average
Key checks
Key Insights
- Humana's sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +9.0%, indicating consistent growth.
- In FY2025, sg&a expense increased 12.8% year-over-year.
- Ranks #4 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.80 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $15.4B | +12.8% |
| FY2024 | $13.7B | +35.3% |
| FY2023 | $10.1B | +0.7% |
| FY2022 | $10.1B | -0.7% |
| FY2021 | $10.1B | +0.7% |
| FY2020 | $10.1B | +53.1% |
| FY2019 | $6.6B | -12.7% |
| FY2018 | $7.5B | +3.2% |
| FY2017 | $7.3B | +1.7% |
| FY2016 | $7.2B | +12.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026